Protagonist Therapeutics (PTGX) Tops Q1 EPS by 54c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q1 EPS of $0.05, $0.54 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $56.37 million versus the consensus estimate of $12.2 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Evercore ISI Upgrades CIENA (CIEN) to Outperform, 'we think the guide is conservative and we see a path to >40% growth'
• Raymond James on Excelerate Energy Inc (EE): 'Positive Long-Term Conviction Reinforced'
• AIAI Holdings signs $200M stock purchase agreement with B. Riley